{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:23:47Z","timestamp":1789230227723,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T00:00:00Z","timestamp":1403654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acne is one of the most common adverse events associated with the use of anticancer agents, such as epidermal growth factor receptor (\n                    <jats:styled-content style=\"fixed-case\">EGFR<\/jats:styled-content>\n                    ) inhibitors. Based on data from several previous reports, we predicted that topical application of\n                    <jats:styled-content style=\"fixed-case\">EGF<\/jats:styled-content>\n                    could improve acne vulgaris. To evaluate the clinical efficacy and safety of topical recombinant human\n                    <jats:styled-content style=\"fixed-case\">EGF<\/jats:styled-content>\n                    (rh\n                    <jats:styled-content style=\"fixed-case\">EGF<\/jats:styled-content>\n                    ) cream for the treatment of facial acne vulgaris. Twenty\n                    <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>\n                    orean adults with mild to moderate acne vulgaris applied topical rh\n                    <jats:styled-content style=\"fixed-case\">EGF<\/jats:styled-content>\n                    cream on one half of the face and a vehicle cream on the other half twice daily for six\u00a0weeks. Clinical assessments were conducted at baseline, two, four, and six\u00a0weeks. Two assessment methods were applied: inflammatory and non\u2010inflammatory acne lesion counts and acne severity score by investigator's global assessment. Skin sebum output level and hydration level were also measured at each visit. All volunteers completed the study. At the final visit, inflammatory acne lesions were reduced by 33.5% on the rh\n                    <jats:styled-content style=\"fixed-case\">EGF<\/jats:styled-content>\n                    \u2010applied side. Non\u2010inflammatory acne lesions also decreased by 25.4%, whereas the lesions on the control side increased. The majority of patients demonstrated improvement on the side of the face where rh\n                    <jats:styled-content style=\"fixed-case\">EGF<\/jats:styled-content>\n                    cream was applied. Sebum output decreased on the rh\n                    <jats:styled-content style=\"fixed-case\">EGF<\/jats:styled-content>\n                    side, and skin hydration level increased on both sides. No severe side effects were observed during the study. Topical rh\n                    <jats:styled-content style=\"fixed-case\">EGF<\/jats:styled-content>\n                    seems to be an effective and safe adjuvant treatment option for mild to moderate acne vulgaris.\n                  <\/jats:p>","DOI":"10.1111\/ijd.12488","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T02:52:04Z","timestamp":1403664724000},"page":"1031-1036","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Topical epidermal growth factor for the improvement of acne lesions: a randomized, double\u2010blinded, placebo\u2010controlled, split\u2010face trial"],"prefix":"10.1111","volume":"53","author":[{"given":"Hyun Kyu","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Dermatology Chung\u2010Ang University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Kwon","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chung\u2010Ang University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapsok","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chung\u2010Ang University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chung\u2010Ang University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeung Nam","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chung\u2010Ang University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Kwun","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chung\u2010Ang University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.5.1369"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/00016489850183214"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.29.18147"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0021-9258(19)83739-0","article-title":"Isolation of mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new born animal","volume":"237","author":"Cohen S","year":"1962","journal-title":"J Biol Chem"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12876204"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0891-8422(23)00491-3","article-title":"Growth factor impact on wound healing","volume":"8","author":"Servold SA","year":"1991","journal-title":"Clin Podiatr Med Surg"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.163.5.1319"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-suppl_4-2"},{"key":"e_1_2_6_11_1","first-page":"32s","article-title":"The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia","volume":"19","author":"Arteaga CL","year":"2001","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.09.005"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051828"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01516.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000342203"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.05.029"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1244831"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04226.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338865"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0012-1606(83)90243-9"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12535112"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000029848"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.8.5047"},{"key":"e_1_2_6_24_1","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"17","author":"P\u00e9rez\u2010Soler R","year":"2003","journal-title":"Oncology"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464210-00002"},{"key":"e_1_2_6_26_1","first-page":"41","article-title":"A review of the literature on benign intracranial hypertension associated with medication","volume":"11","author":"Griffin JP","year":"1992","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198904133201510"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.12488","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.12488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:20:58Z","timestamp":1696288858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.12488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,25]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/ijd.12488"],"URL":"https:\/\/doi.org\/10.1111\/ijd.12488","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718467803.793497492","asserted-by":"object"}]},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,25]]},"assertion":[{"value":"2014-06-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}